Johnson & Johnson's quarterly profit collapsed 96% in the third quarter — nearly wiped out by a one-time charge tied to settling thousands of ovarian-cancer lawsuits over its talc products — even as the healthcare giant posted record sales and raised its outlook for the year.

The company reported GAAP net earnings of just $210 million for the quarter, down from $5.15 billion a year earlier, with diluted earnings per share falling to 9 cents from $2.12, according to J&J's own earnings release. Adjusted diluted EPS, which strips out the one-time charge, came in at $2.59 — down 7.5% from last year but still ahead of Wall Street's roughly $2.53 consensus estimate.

A talc charge, a sales record

The culprit behind the profit crater: a special charge connected to J&J's proposed $5.5 billion settlement of ovarian talc litigation, layered on top of costs from its Firefly Bio acquisition and a Sail Biomedicines collaboration, the company said in its SEC filing. J&J has spent years trying to resolve tens of thousands of lawsuits alleging its talc-based products, including its iconic baby powder, caused cancer; earlier proposed settlements were rejected in bankruptcy court.

Strip out the litigation charge, though, and the underlying business looked healthy. Reported sales climbed 5.9% year-over-year to $25.4 billion. The Innovative Medicine segment — pharmaceuticals — grew nearly 8% to $16.8 billion, driven by the psoriasis drug Tremfya, oncology treatments and the depression drugs Spravato and Caplyta, even as the older drug Stelara continued to drag on growth. MedTech sales rose a more modest 2.5% to $8.6 billion, with strength in electrophysiology offset by flat growth outside the U.S. — soft enough that the company is reportedly weighing a spinoff of part of its orthopedics business, according to Tradingpedia.

The results extend a now-familiar pattern for J&J: strong core pharmaceutical growth repeatedly overshadowed, on paper, by the decades-long fallout from talc litigation that has shadowed the company's balance sheet since the first lawsuits were filed in the 2010s.

"A CLEARER LINE OF SIGHT TO DOUBLE-DIGIT GROWTH BY THE END OF THE DECADE."

That's how CEO Joaquin Duato framed the quarter in the company's official release, pointing to the pharmaceutical pipeline as the engine behind J&J's longer-term ambitions. The company raised its full-year sales guidance to a midpoint of roughly $101.2 billion and nudged its adjusted EPS guidance up to a midpoint of $11.10.

Investors, however, focused on the litigation overhang: J&J shares slipped in premarket trading, and MarketScreener noted that Wall Street analysts issued zero positive EPS revisions against a dozen negative ones in the 90 days leading into the report.

The proposed $5.5 billion talc settlement still depends on enough claimants agreeing to participate, and its final resolution timeline remains uncertain pending court approval. J&J's next major catalyst will be its fourth-quarter results and any further word on the MedTech strategy review.